Blueprint Medicines (BPMC) said Monday it now projects the peak revenue opportunity for its systemic mastocytosis franchise at $4 billion, with Ayvakit likely to achieve annual revenue of $2 billion by 2030.
The company said its BLU-808 treatment for mast cell disorders was well-tolerated at all doses tested in a phase 1 trial in healthy volunteers.
"The results show that BLU-808 performed consistently, with dose-dependent outcomes, including rapid, robust and sustained reductions in serum tryptase across a range of doses, which reinforce the potential for tunable treatment," Blueprint Medicines Chief Scientific Officer Percy Carter said in a press release Sunday.
The company continues to expect product revenue from Ayvakit between $475 million and $480 million for full-year 2024.
Blueprint Medicines shares were up nearly 10% in recent trading.
Price: 95.82, Change: +8.39, Percent Change: +9.60
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。